Subscribe
Machinery & Materials
Markets
Logistics & Cold Chain
Newsletters
Catalent
More from Catalent
Supplier News
Catalent Acquires Erytech Facility in New Jersey
The company has paid $44.5 million for commercial-scale cell therapy development and manufacturing facility, and has entered into an exclusive, long-term supply agreement to support Erytech’s lead product candidate.
Supplier News
Catalent Increasing Temperature-controlled Clinical Supply Capabilities
The company will be expanding its Waigaoqiao Free Trade Zone facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies, as well as additional secondary packaging capabilities.
Pharmaceutical
Catalent: Dose Form Decision Platform
Catalent launches its OptiDose Design Solution to help create differentiated treatments that are successful for innovators, patients, and health care professionals.
COVID-19
OEM Collaboration Against the Spread of COVID
Optima Pharma, Herma, and Rondo-Pak streamline efforts to provide needed machinery in the time-sensitive production of vaccines.
COVID-19
Catalent Incorporates High Speed Cartoning for Vaccine Packaging
In the race to package COVID-19 vaccines, Rondo-Pak hand-assembled hundreds of thousands of cartons with partitions, exact replicas of the cartons Dividella cartoner would soon be producing for Catalent.
COVID-19
HERMA US Supplies High-volume Wraparound Labeling Machines for Biologic Production, COVID-19 Vaccines
HERMA US delivers two HERMA 132M HC wrap-around labelers in just 10 weeks.
Inspection
Partnership to Expedite Installation of Automated Inspection Equipment
Stevanato Group high-speed visual inspection machines will support biologic and vaccine programs at Catalent manufacturing sites in the US and Italy.
COVID-19
Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
The agreement accelerates the rapid scale-up of capacity over the coming months to support the dedicated production of AZD1222.
Home
Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines. Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms